hydromorphone hydrochloride tablet
lannett company, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 2 mg - hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.7)] significant respiratory depression [see warnings and precautions (5.7)] -
acetaminophen and codeine phosphate tablet
american health packaging - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen 300 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not provided adequate analgesia, or are not expected to provide adequate analgesia, - have not been tolerated, or are not expected to be tolerated. acetaminophen and codeine phosphate tablets are contraindicated for: - all children younger than 12 years of age [see warnings ]. - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings ]. acetaminophen and codeine phosphate tablets are contraindicated in patients with: - significant respiratory depression [
hydromorphone hydrochloride tablet
redpharm drug, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.2)] , reserve hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.7)] - acute or severe bronchial asthma in an unmonitored setting or i
hydromorphone hydrochloride tablet
redpharm drug, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.2 ) ], reserve hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.7)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.7)] - known or suspected gastrointe
apvma open use permit 11748- sodium metabisulphite/ table grapes/ phylloxera
apvma permit - sodium metabisulfite(970g/kg) - group m fungicide
apvma open use permit 13955- sodium metabisulphite/ blueberries/ botrytis
apvma permit - sodium metabisulfite(980g/kg) - group m fungicide
uvasys sulphur dioxide generators
tessara pty ltd - sodium metabisulfite; sodium metabisulfite; sodium metabisulfite - slow release generator (inc. flea collars) - sodium metabisulfite mineral-sodium active 358.3 g/kg; sodium metabisulfite mineral-sodium active 375.5 g/kg; sodium metabisulfite mineral-sodium active 339.6 g/kg - fungicide - table grapes - packed - botrytis cinerea
osku-vid grape guards
redox limited - sodium metabisulphite - anhydrous - sachet - sodium metabisulphite - anhydrous mineral-sodium active 980.0 g/kg - fungicide - grapes (packaged) - botrytis | botrytis blight | bunch rot-grey mould | grey mould | grey mould (nesting) | storage rot
memaxia 10 mg film-coated tablet
jamjoom pharmaceuticals company, saudi arabia - memantine hydrochloride - film-coated tablet - 10 mg
memaxia 10 mg film-coated tablet film-coated tablet
jamjoom pharmaceuticals company, saudi arabia - memantine hydrochloride - film-coated tablet - 10 mg